- Home
- WEYS vs TNGX Comparison
WEYS vs TNGX Comparison
Compare WEYS & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEYS
- TNGX
- Stock Information
- Founded
- WEYS 1906
- TNGX 2014
- Country
- WEYS United States
- TNGX United States
- Employees
- WEYS N/A
- TNGX N/A
- Industry
- WEYS Apparel
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- WEYS Consumer Staples
- TNGX Health Care
- Exchange
- WEYS Nasdaq
- TNGX Nasdaq
- Market Cap
- WEYS 303.2M
- TNGX 351.2M
- IPO Year
- WEYS N/A
- TNGX N/A
- Fundamental
- Price
- WEYS $33.12
- TNGX $4.97
- Analyst Decision
- WEYS
- TNGX Strong Buy
- Analyst Count
- WEYS 0
- TNGX 6
- Target Price
- WEYS N/A
- TNGX $12.20
- AVG Volume (30 Days)
- WEYS 14.0K
- TNGX 3.9M
- Earning Date
- WEYS 08-05-2025
- TNGX 08-06-2025
- Dividend Yield
- WEYS 3.23%
- TNGX N/A
- EPS Growth
- WEYS N/A
- TNGX N/A
- EPS
- WEYS 3.04
- TNGX N/A
- Revenue
- WEYS $286,762,000.00
- TNGX $40,990,000.00
- Revenue This Year
- WEYS N/A
- TNGX N/A
- Revenue Next Year
- WEYS N/A
- TNGX N/A
- P/E Ratio
- WEYS $10.77
- TNGX N/A
- Revenue Growth
- WEYS N/A
- TNGX 10.09
- 52 Week Low
- WEYS $25.51
- TNGX $1.03
- 52 Week High
- WEYS $41.05
- TNGX $12.02
- Technical
- Relative Strength Index (RSI)
- WEYS 62.08
- TNGX 70.69
- Support Level
- WEYS $29.72
- TNGX $4.70
- Resistance Level
- WEYS $33.22
- TNGX $5.63
- Average True Range (ATR)
- WEYS 1.10
- TNGX 0.60
- MACD
- WEYS 0.16
- TNGX 0.03
- Stochastic Oscillator
- WEYS 100.00
- TNGX 73.71
About WEYS Weyco Group Inc.
Weyco Group Inc is a company, engaged in the manufacturing, designing, and distribution of footwear. The company designs and markets footwear for men, women, and children. It markets its apparel, accessories, and footwear under the brand names of Florsheim, Nunn Bush, Stacy Adams, BOGS, Rafters, and Forsake. The company organizes its business into two segments; the North American wholesale operations and the North American retail operations. The majority of the company's revenue is generated from the wholesale segment under which its products are sold to footwear, department, and specialty stores, as well as e-commerce retailers. The company has operational footprints in the United States which generates key revenue, Canada, Asia, South Africa, and Australia.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.